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Abstract
As a routine, karyotyping of invasive prenatal samples is performed as an adjunct to referrals for DNA mutation
detection and metabolic testing. We performed a retrospective study on 500 samples to assess the diagnostic
value of this procedure. These samples included 454 (90.8%) chorionic villus (CV) and 46 (9.2%) amniocenteses
specimens. For CV samples karyotyping was based on analyses of both short-term culture (STC) and long-term
culture (LTC) cells. Overall, 19 (3.8%) abnormal karyotypes were denoted: four with a common aneuploidy (trisomy
21, 18 and 13), two with a sex chromosomal aneuploidy (Klinefelter syndrome), one with a sex chromosome
mosaicism and twelve with various autosome mosaicisms. In four cases a second invasive test was performed
because of an abnormal finding in the STC. Taken together, we conclude that STC and LTC karyotyping has
resulted in a diagnostic yield of 19 (3.8%) abnormal cases, including 12 cases (2.4%) with an uncertain significance.
From a diagnostic point of view, it is desirable to limit uncertain test results as secondary test findings. Therefore,
we recommend a more targeted assay, such as e.g. QF-PCR, as a replacement of the STC and to provide parents
the autonomy to choose between karyotyping and QF-PCR.
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Background
Currently, there is no evidence available in the litera-
ture indicating that the prevalence of chromosomal
abnormalities is higher in pregnancies with a referral
for DNA mutation or metabolic testing. Although the
European cytogenetic guidelines for prenatal diagnosis
[1] indicate that both DNA mutation and metabolic
testing do not serve as referral categories for tradi-
tional karyotyping (TK), most prenatal centres world-
wide routinely offer TK as an additional test. In
clinical practice, most couples referred for DNA muta-
tion analysis also opt for TK [2].
It can be disputed, however, whether TK is required
when there is no ap r i o r iincreased risk for chromoso-
mal anomalies as compared to the normal population.
On the other hand, it has been argued that when a risky
invasive prenatal test is performed anyway, it is unethi-
cal not to concomitantly exclude the occurrence of
putative chromosomal abnormalities [3]. With TK, a
wide range of chromosomal abnormalities can be
detected, including alterations in copy number (aneu-
ploidy) and structural chromosomal rearrangements
such as translocations and inversions, being either
balanced or unbalanced. Targeted PCR-based assays
such as multiplex ligation-dependent probe amplifica-
tion (MLPA) or quantitative fluorescent PCR (QF-PCR),
are highly suited for rapid aneuploidy detection (RAD)
of the chromosomes 21, 18, 13, X and Y [4-12]. Pre-
viously, it has been suggested that if the referral reason
is an increased risk of Down’s syndrome, resulting from
a positive screening test result or an advanced maternal
age, karyotyping could effectively be replaced by RAD,
provided that no structural fetal abnormality has been
detected upon ultrasound examination [5,13-17]. The
use of RAD as a targeted, standalone test instead of kar-
yotyping when invasive prenatal testing is performed in
cases with DNA mutation or metabolic test referrals,
has not been studied before. This retrospective study
addresses the clinical impact of TK for samples offered
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Methods
The data in this retrospective study were obtained from
the patient database of the Department of Human
Genetics, Radboud University Nijmegen Medical Centre,
the Netherlands. All procedures were performed with
ethical approval from the local ethical committees. In
the period January 1994 to July 2010, 500 samples from
pregnant women undergoing chorionic villus (CV) sam-
pling or amniocentesis were examined. The reason for
invasive diagnostic testing was a referral for fetal DNA
mutation detection, metabolic diagnostics or other
“non-cytogenetic” reasons, with or without advanced
maternal age (AMA). The samples were from hospitals
participating in the Network Prenatal Diagnostics Nij-
megen (NPDN): Radboud University Nijmegen Medical
Centre, Rijnstate Hospital Arnhem, St. Elisabeth Hospi-
tal and TweeSteden Hospital Tilburg, Medical Spectrum
Twente Enschede, Jeroen Bosch Hospital ‘s-Hertogen-
bosch, and some other hospitals in the Netherlands.
CV samples were split into two portions, one for DNA
mutation or metabolic analysis and one for TK. On CV
samples, both short-term cultures (STC) and long-term
cultures (LTC) were performed. Amniotic fluid (AF)
cells were cultured for TK and, simultaneously, for
DNA isolation. DNA mutation analyses were performed
in different diagnostic centres in the Netherlands. For
metabolic testing, (cell-free) AF was used.
Karyotyping was performed following standard proce-
dures. The results were reviewed retrospectively and
classified as normal or abnormal. Additional or follow-
up studies, such as parental karyotyping in case of a
structural rearrangement or the presence of a marker
chromosome, and fluorescence in situ hybridization
(FISH) in case of insufficient test results, were per-
formed before a definite prenatal karyotype result and
its interpretation were reported. In some cases a second
prenatal invasive procedure was performed. The test
results of DNA mutation and metabolic testing were
retrieved from the patient’s records.
Results
The prenatal test results of 454 (90.8%) chorionic villus
(CV) and 46 (9.2%) amniotic fluid (AF) samples (500 in
total) were assessed. DNA mutation analysis referrals
classified in normal and abnormal karyotypes are shown
in Table 1. Overall, 481 (96.2%) normal karyotypes (46,
XX or 46, XY) were found. The most common reasons
for DNA testing were Fragile X syndrome and Hunting-
ton disease (11.4% and 7.8%, respectively). Overall, TK
resulted in 19 (3.8%) abnormal karyotypes (18 CV sam-
ples and 1 AF sample). The maternal age at sampling
was ≥ 36 years in 117 (23.4%) samples and resulted in 8
(6.8%) abnormal karyotypes (mean maternal age 37.9
years, median 37.5 years). The maternal age at sampling
was < 36 years in 383 (76.6%) samples, and resulted in
11 (2.9%) abnormal karyotypes (mean maternal age 29.9
years, median age 30.0 years) (Figures 1 and 2). The 19
Table 1 Ranking of diseases for DNA mutation analysis and karyotyping
Disease N Normal
karyotype
≥ 36 years Abnormal
karyotype
Abnormal karyotype (≥ 36
years)
Case
no.
(< 36 years)
Fragile X syndrome 57 57 9
Huntington’s disease 39 37 6 2 1,9
Duchenne muscular dystrophy 33 32 6 1 2
Spinal Muscular Atrophy 30 27 14 3 5,6,13
Myotonic dystrophy 29 26 5 2 1 3,11,1
Hurler syndrome 8 7 2 1 4
Spondyloepiphyseal dysplasia 7 6 1 1 12
Hemophagocytic
lymphohistiocytosis
54 1 1 1 8
Monoamine oxidase A deficiency 5 4 2 1 10
X-linked MR 5 4 1 17
Paternity testing 3 2 2 1 19
Wilms tumors 3 2 1 1 15
Canavan disease 2 1 2 1 7
Nonsyndromic hearing loss 2 1 1 16
Nail-patella syndrome 1 0 1 8
Other diseases 271 271 56
Total 500 481 117 11 8
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3. These included all, except one, CV samples: 4 cases
with a common aneuploidy (trisomy 21, 18 and 13), 2
cases with a sex chromosomal aneuploidy (Klinefelter
syndrome), one sex chromosomal mosaicism in amniotic
fluid cells and different autosomal mosaicisms in 12 CV
samples. These latter samples included four aberrations
present in STC but absent in LTC, 4 aberrations present
in LTC but absent in STC and 4 aberrations present in
both STC and LTC.
In 4 of the aberrations present in STC but not in
LTC, additional testing by amniocenteses showed a nor-
mal fetal karyotype and, therefore, the mosaicism in the
CV samples appeared to be a confined placental mosai-
cism (CPM type I).
I n3o ft h e4a b e r r a t i o n sp r e s e n ti nL T Cb u tn o ti n
STC, DNA mutation analyses were positive and the
respective pregnancies were terminated. Therefore no
cytogenetic follow-up testing was performed. In the 4
th
case the percentage of tetraploid cells in the LTC was
46%. Although tetraploid cells are common in CV
samples, particularly in LTC, this high percentage was a
reason to report this finding and to continue pregnancy
follow-up by ultrasound examination. The child was
born pre-term at 33 weeks of pregnancy without conge-
nital anomalies.
The abnormalities detected in both STC and LTC
included two low-grade sex chromosome mosaicisms
(cases 15 and 16). Case 15 appeared positive upon DNA
mutation analysis. Therefore the pregnancy was termi-
nated. In case 16 only 1 out of 4 metaphases in STC and 1
out of 28 metaphases in LTC showed a 45, X karyotype,
all other metaphases were 46, XY. No follow-up amnio-
centesis was performed and the pregnancy was followed
by ultrasound examination showing a normal male fetus.
The 3
rd sample showed a paternally inherited 45, X, inv(Y)
karyotype. The 4
th showed a marker chromosome in a sin-
gle metaphase in both STC and LTC. The parental karyo-
types were normal. The fetus appeared positive upon
DNA mutation testing. The pregnancy was terminated.
Taken together, we conclude that karyotyping resulted
in a diagnostic yield of 19 (3.8%) abnormal karyotypes,
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Figure 1 Flow diagram for karyotyping of 500 prenatal samples.
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rise to uncertainty to prospective parents about the fetal
prognoses.
Discussion
In case an invasive prenatal test is performed for DNA
mutation or metabolic testing, most prenatal centres
offer traditional karyotyping (TK) as an additional test
to exclude the presence of chromosome abnormalities.
There is also no evidence from the literature that the
prevalence of chromosomal abnormalities is higher in
pregnancies with a referral for DNA mutation or meta-
bolic analysis. The majority of the cases included in our
current study represented CV samples (91.2%) because
DNA isolation for mutation detection can be performed
immediately after tissue sampling and a diagnostic result
can be obtained in the first trimester. In contrast, AF
cells have to be cultured first and, hence, a diagnostic
result can only be obtained in the second trimester. In
total, 19 (3.8%) abnormal karyotypes were denoted.
When no cytogenetic testing was performed in the
group of pregnant women < 36 years 11 (2.9%) cytoge-
netic aberrations would remained undetected. In 8 of
these 11 it was uncertain whether the abnormal karyo-
type represented the true genetic constitution of the
fetus due to mosaicisms. Mosaicisms are thought to be
present in ~1% of CV samples, and have been confirmed
in the fetus in 5-25% of these cases [18,19]. In our study
population of 454 CV samples 12 (2.6%) showed a chro-
mosome mosaicism with uncertain clinical impact.
Uncertain diagnostic results are leading to parental anxi-
ety and mostly require follow-up testing. For example in
cases 9 and 11 (Tables 2 and 3), next to additional TK
of amniotic fluid, additional DNA testing is required to
Figure 2 Boxplot showing the maternal age distribution in normal and abnormal karyotype results in the groups younger or 36 years
and older. The box plots illustrate the median, 25th, and 75th percentiles. o Value more than 1.5 box-lengths from 75th/25th percentile
(outliers).
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and 15. Prenatal UPD(7) testing, however, is question-
able considering the mild phenotype [20]. The risk of
UPD(15) when trisomy 15 mosaicism has been detected,
upon CV or AF analysis, has been estimated to range
from 11% to 29% [21,22].
The overall percentage of mosaicism in our study
(2.4%) score slightly higher as the 1-2% reported in the
literature [18,19,23]. A possible explanation is the use of
both the STC and LTC procedure. As individual labora-
tories use different protocols to examine CV samples
(LTC only, STC combined with LTC or QF-PCR alone),
the incidence of mosaicism is likely to vary to some
degree between laboratories.
With the implementation of targeted molecular-cyto-
genetic tests such as MLPA and QF-PCR, the question
arises whether TK should remain the gold standard or
could be replaced by RAD for pregnancies at risk for
common aneuploidies. RAD test results are unequivocal
and available within 1-2 days, which considerably
reduces parental anxiety [16]. In case of thalassaemia,
for example, RAD has already shown to be the best
approach for the detection of chromosomal abnormal-
ities when prenatal invasive testing is performed [3].
Next to the possibility to recognise maternal cell con-
tamination, RAD is also cost-effective particularly when
performed large scale [24]. For pregnancies with an
increased risk of Down syndrome, a change of policy
from full karyotype analysis to rapid molecular aneu-
ploidy testing would result in a failure to detect chro-
mosome abnormalities that may have clinical
consequences. This residual risk has been estimated to
be 0.07% [25-27]. Next to the debate of targeted RAD
replacing TK there is a discussion whether the scope of
diagnostic testing should be broader than karyotyping.
Although broadening the scope of testing benefits in
terms of clinically relevant findings that would otherwise
be missed, a serious challenge is that, with the present
state of knowledge, results of such testing could be diffi-
cult to interpret [28], creating parental anxiety, uncer-
tainty and unnecessary termination of pregnancy. Our
overall tendency towards broadening the scope of prena-
tal testing is using genome-wide microarray analysis in
high-risk pregnancies (e.g. with fetal ultrasound abnorm-
alities) and narrowing (targeting) the scope in low-risk
pregnancies.
In our prenatal diagnostic service, RAD (QF-PCR) is
already implemented as replacement for the STC in all
CV samples and offered as stand-alone test for pregnan-
cies with an increased risk of Down syndrome, such as a
positive screening test result or an advanced maternal
age, as a test of choice. With the application of a cell
dissociation protocol steps are taken to prevent fully dis-
crepant results between cytotrophoblasts and mesenchy-
mal core cells for the chromosomes 13, 18, 21, X and Y.
Herewith, the cytotrophoblast cells (analyzed in STC)
Table 2 List of nineteen abnormal karyotype results
Case no Karyotype STC Karyotype
LTC
≥ 36
years
Karyotype
AF
Follow-up
testing
Type Pregnancy
follow-up and
clinical outcome
DNA analysis or
metabolic testing
Aneuploidy in STC
and LTC
1 47, XXY[3] 47, XXY[9] no - TOP not affected
2 FISH(13,18)×2,
(X, Y)×1, (21)×3
47, XY, +21
[8]
yes - TOP not determined
3 47, XY, +21[2] 47, XY, +21
[8]
no - TOP not determined
4 47, XXY[4] 47, XXY[8] no - TOP not affected
5 47, XY, +18[3] 47, XY, +18
[11]
yes - TOP not determined
6 47, XY, +21[4] 47, XY, +21
[8]
yes - TOP not determined
Aberration in STC,
not in LTC
7 47, XX, +3[3]/
46, XX[4]
46, XX[11] yes AF 46, XX CPM
I
continued not affected
8 45, X[4] 46, XX[29] no AF 46, XX CPM
I
continued not affected
9 47, XY, +15[2]/
46, XY[2]
46, XY[29] no AF 46, XY,
no UPD(15)
CPM
I
continued not affected
10 48, XY, +3, +21
[5]/
46, XY[6]
46, XY[16] no AF 46, XY CPM
I
continued not affected
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tested for RAD separately [29,30] and, thus, discrepan-
cies as in cases 8 and 10 would have been detected if
RAD were used. The application of RAD to replace kar-
yotyping in both STC and LTC will prevent findings
without clinical relevance and/or uncertain outcome.
Limitations of this retrospective study should be
addressed. First, this study does not represent all preg-
nant women primary referred for molecular or meta-
bolic testing. Some of the pregnancies were terminated
because of a positive DNA mutation result and, there-
fore, the impact of the respective mosaicisms could not
be evaluated. Secondly, although we already implemen-
ted QF-PCR as stand-alone test in our routine prenatal
practice as a test of choice for pregnant women with an
increased risk for Down syndrome, the QF-PCR test was
not performed on the cases presented in this study.
Taken together, we conclude that there is additional
diagnostic value of TK. However, there is also a need to
limit uncertain test results as secondary findings. In this
population with a low risk for a chromosomal aneu-
ploidy, we recommend to implement QF-PCR as
replacement of the STC and to give parents the auton-
omy to choose between karyotyping and QF-PCR.
The results of this study are in line with those
reported by Tse et al [3], showing that RAD seems to
be the best approach for the detection of chromosomal
abnormalities when invasive prenatal testing is per-
formed for the diagnosis of thalassaemia. The broader
application of this study may create awareness and
reconsideration of national standards for prenatal cyto-
genetic testing, a step towards international harmonized
procedures and prenatal care.
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Table 3 List of nineteen abnormal karyotype results (continued)
Case no Karyotype
STC
Karyotype
LTC
≥ 36
years
Karyotype
AF
Follow-up testing Type Pregnancy
follow-up and clinical
outcome
DNA analysis or
metabolic testing
Aberration in
LTC, not in STC
11 46, XX[4] 47, XX, +7
[8]/46, XX[21]
no - TOP* affected
12 46, XX[50] 92, XXXX
[23]/46, XX
[27]
no - partus 33 weeks, livebirth,
no congenital anomalies
not affected
13 46, XY[4] 47, XY, +?18
[2]/
46, XY[37]
yes - unknown affected
14 46, XX[8] 47, XX, +?20
[2]/46, XX[7]
yes - TOP* affected
Aberration in
STC and LTC
15 45, X[3]/46,
XX[1]
45, X[1]/46,
XX[8]
yes skin biopsy post
partum 46, XX
CPM
III
TOP* affected
16 45, X[1]/46,
XY[2]
45, X[1]/46,
XY[28]
no - continued, livebirth, no
congenital anomalies
not affected
17 46, X, inv(Y)
[5]
46, X, inv(Y)
[9]
no inv(Y)pat TOP* affected
18 47, XX,
+mar[1]/
46, XX[3]
47, XX, +mar
[1]/
46, XX[28]
no parental karyotype
normal
TOP affected*
Amniotic fluid
sample
19 - - yes 45, X[10]/
47, XXX[9]/
46, XX[2]
karyotype blood post
partum 45, X[9]/
47, XXX[33]/46, XX[8],
normal phenotype
continued, livebirth, no
congenital anomalies
not affected
* TOP: termination of pregnancy based on affected pregnancy (positive DNA analysis or metabolic testing); CPM: confined placental mosaicism
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Page 6 of 7long-term culture; MLPA: multiplex ligation-dependent probe amplification;
NPDN: Network Prenatal Diagnostics Nijmegen; QF-PCR: quantitative
fluorescent polymerase chain reaction; RAD: rapid aneuploidy detection; STC:
short-term culture; TK: traditional karyotyping; UPD: uniparental disomy.
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